Carlson Capital’s Taysha Gene Therapies TSHA Stock Holding History

Carlson Capital’s Portfolio TSHA Stock Details TSHA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-484,000	Closed	-$320K	–	156
2023 Q2	$320K	Sell	484,000 -20,000	-4%	-$14.5K	0.03%	113
2023 Q1	$402K	Sell	504,000 -56,000	-10%	-$72.3K	0.04%	107
2022 Q4	$1.27M	Buy	560,000 +360,000	+180%	+$729K	0.1%	101
2022 Q3	$386K	Buy	200,000 +35,000	+21%	+$127K	0.03%	117
2022 Q2	$614K	Buy	+165,000	New	+$655K	0.04%	116

Other funds holding TSHA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

ACP

Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Carlson Capital's TSHA Position: Q3 2023 in Review

Carlson Capital sold out of Taysha Gene Therapies (TSHA) in Q3 2023, closing a stake of 484,000 shares — an estimated $320K sold.

Carlson Capital first reported a position in TSHA in Q2 2022 and held it in 5 quarters. The position peaked at $1.27M in Q4 2022. 63 funds tracked by Wall St. Rank hold TSHA as of Q3 2023.

Carlson Capital reported no remaining Taysha Gene Therapies position as of Q3 2023 after selling out during the quarter.
Carlson Capital sold 484,000 Taysha Gene Therapies shares in Q3 2023, an estimated $320K.
Carlson Capital first reported a position in Taysha Gene Therapies in Q2 2022 and held it in 5 quarters.
Carlson Capital's Taysha Gene Therapies position peaked at $1.27M in Q4 2022.
63 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q3 2023.

Based on Carlson Capital's 13F filing for Q3 2023, filed 14 Nov 2023.